☰

Shivangi Awasthi - Publications

Affiliations: 
Pharmaceutical Sciences University of Maryland School of Pharmacy 
Tree Info Similar researchers PubMed Report error

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Zhang X, Nguyen KD, Rudnick P, Roper N, Kawaler E, Maity TK, Awasthi S, Gao S, Biswas R, Venugopalan A, Cultraro CM, Fenyö D, Guha U. Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879V. Molecular & Cellular Proteomics : McP. PMID 30617155 DOI: 10.1074/Mcp.Ra118.001266  0.385
2019 Xhang X, Nguyen KDP, Rudnick P, Roper N, Kawaler E, Maity TK, Awasthi S, Gao S, Biswas R, Venugopalan A, Cultraro C, Fenyo D, Guha U. Abstract 4528: Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879V Cancer Research. 79: 4528-4528. DOI: 10.1158/1538-7445.Sabcs18-4528  0.496
2018 Awasthi S, Maity T, Oyler BL, Zhang X, Goodlett DR, Guha U. Dataset describing the development, optimization and application of SRM/MRM based targeted proteomics strategy for quantification of potential biomarkers of EGFR TKI sensitivity. Data in Brief. 19: 424-436. PMID 29900338 DOI: 10.1016/J.Dib.2018.04.086  0.73
2018 Awasthi S, Maity T, Oyler BL, Qi Y, Zhang X, Goodlett DR, Guha U. Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma. Journal of Proteomics. PMID 29660496 DOI: 10.1016/J.Jprot.2018.04.005  0.714
2017 Zhang X, Maity T, Kashyap MK, Bansal M, Venugopalan A, Singh S, Awasthi S, Marimuthu A, Jacob HK, Belkina N, Pitts S, Cultraro CM, Gao S, Kirkali F, Biswas R, et al. Quantitative tyrosine phosphoproteomics of EGFR tyrosine kinase inhibitor-treated lung adenocarcinoma cells reveals potential novel biomarkers of therapeutic response. Molecular & Cellular Proteomics : McP. PMID 28331001 DOI: 10.1074/Mcp.M117.067439  0.467
2017 Awasthi S, Zhang X, Maity T, Oyler BL, Goodlett DR, Guha U. Abstract 2203: A SRM/MRM based targeted proteomics strategy for absolute quantification of potential biomarkers of TKI sensitivity in EGFR mutated lung adenocarcinoma Cancer Research. 77: 2203-2203. DOI: 10.1158/1538-7445.Am2017-2203  0.723
2016 Tran BQ, Barton C, Feng J, Sandjong A, Yoon SH, Awasthi S, Liang T, Khan MM, Kilgour DP, Goodlett DR, Goo YA. Glycosylation characterization of therapeutic mAbs by top- and middle-down mass spectrometry. Data in Brief. 6: 68-76. PMID 26793758 DOI: 10.1016/J.Dib.2015.11.031  0.672
2016 Tran BQ, Barton C, Feng J, Sandjong A, Yoon SH, Awasthi S, Liang T, Khan MM, Kilgour DPA, Goodlett DR, Goo YA. Glycosylation characterization of therapeutic mAbs by top- and middle-down mass spectrometry Data in Brief. 6: 68-76. DOI: 10.1016/j.dib.2015.11.031  0.688
2015 Tran BQ, Barton C, Feng J, Sandjong A, Yoon SH, Awasthi S, Liang T, Khan MM, Kilgour DP, Goodlett DR, Goo YA. Comprehensive glycosylation profiling of IgG and IgG-fusion proteins by top-down MS with multiple fragmentation techniques. Journal of Proteomics. PMID 26485299 DOI: 10.1016/J.Jprot.2015.10.021  0.665
Show low-probability matches.